Given the multiple pathways involved in the pathophysiology of NIHL, we hypothesized that the EGFR inhibitor could synergize with an inhibitor of the CDK2 pathway and thus increase the levels of protection against NIHL. Here, CDK2 is linked to noise induced hearing loss.